Update: Ongoing Zika Virus Transmission — Puerto Rico, November 1, 2015–July 7, 2016
July 29, 2016
The Puerto Rico Department of Health (PRDH) and CDC devised a Zika virus response strategy after the reporting of the first locally acquired case of Zika virus infection in Puerto Rico in December 2015. During November 1, 2015–July 7, 2016, a total of 23,487 persons with suspected cases of Zika virus disease infection or Guillain-Barré syndrome or who were pregnant but asymptomatic were evaluated by PRDH and CDC Dengue Branch; 5,582 (24%) confirmed and presumptive positive Zika virus cases were identified.
Graduated Driver Licensing Night Driving Restrictions and Drivers Aged 16 or 17 Years Involved in Fatal Night Crashes — United States, 2009–2014
July 29, 2016
During 2009–2014, approximately one third of drivers aged 16 or 17 years in the United States involved in fatal crashes crashed in the period from 9:00 p.m. to 5:59 a.m.; 57% crashed before 12:00 a.m. Night driving restrictions (NDRs) have been shown to reduce crashes among newly licensed teens, with higher reductions associated with NDRs starting at 10:00 p.m. or earlier. However, NDRs begin at 12:00 a.m. or later in the District of Columbia and 23 of the 49 states that include them in their Graduated Driver Licensing system.
Mumps Outbreak at a University and Recommendation for a Third Dose of Measles-Mumps-Rubella Vaccine — Illinois, 2015–2016
July 29, 2016
A large outbreak of mumps occurred at the University of Illinois at Urbana-Champaign during April 2015–May 2016; 89% of patients with mumps had received at least 2 doses of measles-mumps-rubella
(MMR) vaccine, and a third dose was recommended as a control measure. The rationale for the recommendation of a third MMR dose included a consideration of seasonal trends and characteristics of the population at risk.
Recommendations and Reports
U.S. Medical Eligibility Criteria for Contraceptive Use, 2016
July 29, 2016
The 2016 U.S. Medical Eligibility Criteria for Contraceptive Use (U.S. MEC) comprises recommendations for the use of specific contraceptive methods by women and men who have certain characteristics or medical conditions. Notable updates since the 2010 U.S. MEC include the addition of recommendations for women with cystic fibrosis, women with multiple sclerosis, and women receiving certain psychotropic drugs or St. John’s wort; revisions to the recommendations for emergency contraception, including the addition of ulipristal acetate; and revisions to the recommendations for postpartum women; women who are breastfeeding; women with known dyslipidemias, migraine headaches, superficial venous disease, gestational trophoblastic disease, sexually transmitted diseases, and human immunodeficiency virus; and women who are receiving antiretroviral therapy. These recommendations are a companion document to the CDC U.S. Selected Practice Recommendations for Contraceptive Use, 2016.
U.S. Selected Practice Recommendations for Contraceptive Use, 2016
July 29, 2016
The 2016 U.S. Selected Practice Recommendations for Contraceptive Use (U.S. SPR) addresses common issues regarding initiation and use of specific contraceptive methods. The information in this report updates the 2013 U.S. SPR. Major updates include 1) revised recommendations for starting regular contraception after the use of emergency contraceptive pills and 2) new recommendations for the use of medications to ease insertion of intrauterine devices. These recommendations are a companion document to the CDC U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.
Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance —The Gonococcal Isolate Surveillance Project,27 Sites, United States, 2014
July 15, 2016
Gonorrhea is the second most commonly reported notifiable disease in the United States. Prevention of sequelae and of transmission to sexual partners relies on prompt detection and effective treatment. However, treatment has been compromised by the absence of routine antimicrobial susceptibility testing in clinical care and evolution of antimicrobial resistance to the antibiotics used to treat gonorrhea. Dual therapy with ceftriaxone plus azithromycin is the only recommended gonorrhea treatment, and the potential threat of cephalosporin-resistant gonorrhea is a cause for concern. This report presents comprehensive surveillance data from the Gonococcal Isolate Surveillance Project and describes gonococcal antimicrobial susceptibility patterns in the United States during 2000–2014. Antimicrobial susceptibility surveillance data can be used to develop national treatment recommendations, set research and prevention priorities, and communicate best treatment practices to health care providers.
CDC’s Response to the 2014–2016 Ebola Epidemic — West Africa and United States
July 8, 2016
This historic 2014-2016 Ebola Epidemic in West Africa required a massive international response by multiple partners to assist the affected countries. This supplement present reports that chronicle major aspects of CDC’s response to the Ebola epidemic.
Summary of Notifiable Infectious Diseases and Conditions
The official statistics, in tabular and graphic form, for the reported occurrence of nationally notifiable infectious diseases
Summary of Notifiable Noninfectious Conditions and Disease Outbreaks
The official statistics, in tabular and graphic form, for the reported occurrence of nationally notifiable noninfectious conditions and disease outbreaks in the United States.
- Page last reviewed: July 29, 2016
- Page last updated: July 29, 2016
- Content source: